News &amp; Updates

Brolucizumab prolongs interval of anti-VEGF injections in nAMD patients

Treatment with brolucizumab results in a longer interval between injections of antivascular endothelial growth factor (anti-VEGF) agents for most treatment-experienced eyes, especially those with shorter intervals before switching, while maintaining or improving visual acuity (VA), reports a study.

Brolucizumab prolongs interval of anti-VEGF injections in nAMD patients

Dexamethasone superior to ranibizumab, methotrexate for recurrent uveitic ME

01 Sep 2023 by

Treatment with dexamethasone implant results in better outcomes for patients with persistent or recurrent uveitic macular edema (ME) at 12 weeks when compared with methotrexate or ranibizumab, a study has shown. The risk of intraocular pressure (IOP), however, is higher with dexamethasone, but elevations to levels of 30 mm Hg or more are rare.

Dexamethasone superior to ranibizumab, methotrexate for recurrent uveitic ME

Original New Drug Application Approvals by US FDA (16-31 August 2023)

New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 August 2023)

Antibiotic use, resistance rates low after a decade of stewardship efforts in SG

Ten years since the implementation of antimicrobial stewardship programmes (ASP) in Singapore, the use of several types of antibiotics has dropped, followed by reductions in antimicrobial resistance across several classes, as reported in a study.

Antibiotic use, resistance rates low after a decade of stewardship efforts in SG

AI predicts blood concentration of quetiapine in patients with schizophrenia, depression

A machine learning model that incorporates artificial intelligence (AI) techniques to predict the blood concentration of quetiapine is feasible for clinical medication guidance in patients with schizophrenia and depression, reports a real-world study.

AI predicts blood concentration of quetiapine in patients with schizophrenia, depression

31 Aug 2023

US FDA greenlights first pill for postpartum depression

The US Food and Drug Administration (FDA) has approved the first oral medication for postpartum depression in adults, giving clinicians a new therapeutic option for this debilitating condition.

US FDA greenlights first pill for postpartum depression

Statin cuts CV risk in patients with HIV

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

Statin cuts CV risk in patients with HIV

Jakinibs for AD in Asians: Is one better than the other?

Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis (AD) as shown in an Asian retrospective cohort study.

Jakinibs for AD in Asians: Is one better than the other?